Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration

Journal of Vascular Surgery

Volumn 36, Issue 1, 2002, Pages 150-157

  Porter, Karen E ^a   Naik, Jagjeeth ^b   Turner, Neil A ^a   Dickinson, Timothy ^b   Thompson, Matthew M ^b   London, Nicholas J M ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; MARIMASTAT; MATRIGEL; MATRIX METALLOPROTEINASE; SIMVASTATIN; ENZYME INHIBITOR; GELATINASE A; HYDROXAMIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID;

ARTICLE; BASEMENT MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; INTIMA; PRIORITY JOURNAL; SAPHENOUS VEIN; SMOOTH MUSCLE FIBER; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; LEUKOCYTE MIGRATION INHIBITION TEST; VASCULAR SMOOTH MUSCLE;

CELL MIGRATION INHIBITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; ENZYME INHIBITORS; HUMANS; HYDROXAMIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEVALONIC ACID; MUSCLE, SMOOTH, VASCULAR; SAPHENOUS VEIN; SIMVASTATIN; TUNICA INTIMA;

EID: 0036632158     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1067/mva.2002.122029     Document Type: Article

References (44)

1. Angelini GD, Newby AC. The future of saphenous vein as a coronary artery bypass conduit. Eur Heart J 1989;10:273-80.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature 1993;362:801-9.
3. Southgate KM, Davies M, Booth RFG, Newby AC. Involvement of extracellular matrix degrading metalloproteinases in rabbit aortic smooth muscle cell proliferation. Biochem J 1992;288:93-9.
4. Newby AC, Southgate KM, Davies M. Extracellular matrix degrading metalloproteinases in the pathogenesis of arteriosclerosis. Basic Res Cardiol 1994;89(Suppl 1):59-70.
5. Galis Z, Muszynski M, Sukhova G, Morrissey E, Unemori EN, Lark MW, et al. Cytokine-stimulated human vascular smooth muscle cells synthesise a complement of enzymes required for extracellular matrix digestion. Circ Res 1994;75:181-9.
6. Sperti G, van Leeuwen RTJ, Quax PHA, Maseri A, Kluft C. Cultured rat aortic vascular smooth muscle cells digest naturally produced extracellular matrix. Involvement of plasminogen-dependent and plasminogen-independent pathways. Circ Res 1992;71:385-92.
7. Porter KE, Thompson MM, Loftus IM, McDermott EM, Jones L, Crowther M, et al. Production and inhibition of the gelatinolytic matrix metalloproteinases in a human model of vein graft stenosis. Eur J Vasc Endovasc Surg 1999;17:404-12.
8. George SJ, Zaltsman AB, Newby AC. Surgical preparative injury and neointima formation increase MMP-9 expression and MMP-2 activation in human saphenous vein. Cardiovasc Res 1997;33:447-59.
9. Porter KE, Varty K, Jones L, Bell PRF, London NJM. Human saphenous vein organ culture: a useful model of intimal hyperplasia? Eur J Vasc Endovasc Surg 1996;11:48-58.
10. Soyombo AA, Angelini GD, Bryan AD, Jasani B, Newby AC. Intimal proliferation in an organ culture of human saphenous vein. Am J Pathol 1990;137:1401-10.
11. Porter KE, Loftus IM, Peterson M, Bell PRF, London NJM, Thompson MM. Marimastat inhibits neoitimal thickening in a model of human vein graft stenosis. Br J Surg 1998;85:1373-7.
12. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997;15:61-75.
13. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/Tex-CAPS. JAMA 1998;279:1615-22.
14. Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ, Jones PH, West MS. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations. (Lipoprotein and Coronary Arteriosclerosis Study [LCAS]). Am J Cardiol 1997;80:278-86.
15. Riegger G, Abletshauser C, Ludwig M, Schwandt P, Widimsky J, Weidinger G, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis 1999;144:263-70.
16. Nègre-Aminou P, van Vliet AK, van Erck M, van Thiel, GC, van Leeuwen RE, Cohen LH. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1997;1345:259-68.
17. Nègre-Aminou P, van Erck M, van Leeuween REW, Collard JG, Cohen LH. Differential effect of simvastatin on various signal transduction intermediates in cultured human smooth muscle cells. Biochem Pharmacol 2001;61:991-8.
18. Kouchi H, Nakamura K, Fushimi K, Sakaguchi M, Miyazaki M, Ohe T, et al. Manumycin A, inhibitor of ras farnesyltransferase, inhibits proliferation and migration of rat vascular smooth muscle cells. Biochem Biophys Res Commun 1999;264:915-20.
19. Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate smooth muscle cell proliferation by preventing rho GTPase-induced down-regulation of p27 (Kip1). J Biol Chem 1999;274:21926-31.
20. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999;84:413-28.
21. Ganné F, Vasse M, Beaudeux J-L, Peynet J, Francois A, Mishal Z, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes. Thromb Haemost 2000;84:680-8.
22. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998;18:1671-8.
23. Wang IK, Lin-Shiau SY, Lin JK. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. oncology 2000;59:245-54.
24. Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001;22:1139-48.
25. Zhang BZ, Ye S, Herrmann S-M, Eriksson P, de Maat M, Evans A, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999;99: 1788-94.
26. Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res 1996;78:38-43.
27. Wills A, Thompson MM, Crowther M, Brindle NP, Nasim A, Sayers RD, et al. Elastase-induced matrix degradation in arterial organ cultures: an in vitro model of aneurysmal disease. J Vasc Surg 1996;24: 667-9.
28. Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol 1996;16:28-33.
29. Mason DP, Kenagy RD, Hasenstab D, Bowen-Pope DF, Seifert RA, Coats S, et al. Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodelling in the injured rat carotid artery. Circ Res 1999;85:1179-85.
30. Southgate KM, Mehta D, Izzat MB, Newby AC, Angelini GD. Increased secretion of basement membrane-degrading metalloproteinases in pig saphenous vein into carotid artery interposition grafts. Arterioscler Thromb Vasc Biol 1999;19:1640-9.
31. Indolfi C, Cioppa A, Stabile E, Di Lorenzo E, Esposito G, Pisani A, et al. Effects of hydroxymethylglutarylcoenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol 2000;35:214-21.
32. Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L, et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998;137(Suppl):S101-9.
33. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev 2001;81:153-208.
34. Ai S, Kuzuya M, Koike T, Asai T, Kanda S, Maeda K, et al. Rho-Rho kinase is involved in smooth muscle cell migration through myosin light chain phosphorylation-dependent and independent pathways. Atherosclerosis 2001;155:321-7.
35. Work LM, McPhaden AR, Pyne NJ, Pyne S, Wadsworth RM, Wainwright CL. Short-term local delivery of an inhibitor of Ras farnesyltransferase prevents neointima formation in vivo after porcine coronary balloon angioplasty. Circulation 2001;104:1538-43.
36. Vincent L, Chen W, Hong L, Mirshahi F, Mishal Z, Mirshahi-Khorassani T, et al. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett 2001;495:159-66.
37. Lovdahl C, Thyberg J, Hultgardh-Nilsson A. The synthetic metalloproteinase inhibitor batimastat suppresses injury-induced phosphorylation of MAP kinase ERK1/ERK2 and phenotypic modulation of arterial smooth muscle cells in vitro. J Vasc Res 2000;37:345-54.
38. Johnson S, Knox A. Autocrine production of matrix metalloproteinase-2 is required for human airway smooth muscle proliferation. Am J Physiol 1999;277:L1109-17.
39. Christenson JT. Pre-operative lipid control with simvastatin reduces the risk for graft failure already 1 year after myocardial revascularization. Cardiovasc Surg 2001;9:33-43.
40. Hagenaars T, Gussenhoven EJ, van Sambeek MRHM, Jukema JW, Kranendonk SE, Bom N. Effect of simvastatin on restenosis after percutaneous transluminal angioplasty of femoropoliteal arterial obstruction. Am J Cardiol 2000;86:774-6.
41. Indolfi C, Cioppa A, Stabile E, Di Lorenzo E, Esposito G, Pisani A, et al. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation after vascular injury. J Am Coll Cardiol 1999;35:214-21.
42. Igarashi M, Takeda Y, Mori S, Ishibashi N, Komatsu E, Takahashi K, et al. Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth. Br J Pharmacol 1997;120:1172-8.
43. Ferrell M, Fuster V, Gold HK, Chesebro JH. A dilemma for the 1990 Y Choosing appropriate experimental models for the prevention of restenosis. Circulation 1992;85:1630-1.
44. Corsini A, Arnaboldi L, Raiteri M, Quarato P, Faggiotto A, Paoletti R, et al. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes. Pharmacol Res 1996;33:55-61.